Versant Capital Management, Inc Cytek Biosciences, Inc. Transaction History
Versant Capital Management, Inc
- $431 Million
- Q3 2024
A detailed history of Versant Capital Management, Inc transactions in Cytek Biosciences, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 1,028 shares of CTKB stock, worth $6,671. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,028Holding current value
$6,671% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding CTKB
# of Institutions
134Shares Held
71.7MCall Options Held
400Put Options Held
0-
Black Rock Inc. New York, NY17.1MShares$111 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$76.4 Million0.0% of portfolio
-
Brown Capital Management LLC Baltimore, MD9.49MShares$61.6 Million1.15% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E96.66MShares$43.2 Million0.85% of portfolio
-
State Street Corp Boston, MA4.17MShares$27 Million0.0% of portfolio
About Cytek Biosciences, Inc.
- Ticker CTKB
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 134,627,008
- Market Cap $874M
- Description
- Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers ...